Skip to main content
. 2021 Aug 6;42(6):1015–1025. doi: 10.1007/s00296-021-04955-8

Fig. 2.

Fig. 2

TNF-blocking capacity of adalimumab, golimumab and etanercept. Gray circles (adalimumab) represent patients with low level of ADAb (< 23 AU/mL) and black circles patients with high level of ADAb (> 23 AU/mL). In golimumab users, black circles represent patients who are positive for ADAb